Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 2—February 2012


Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infections, United States, 2010–11

Aaron D. Storms, Larisa V. Gubareva, Su Su, John T. Wheeling, Margaret Okomo-Adhiambo, Chao-Yang Pan, Erik Reisdorf, Kirsten St. George, Robert Myers, Jason T. Wotton, Sara Robinson, Brandon Leader, Martha Thompson, Marjorie Shannon, Alexander Klimov, Alicia M. FryComments to Author , and for the US Antiviral Resistance Surveillance Working Group
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.D. Storms, L.V. Gubareva, S. Su, J.T. Wheeling, M. Okomo-Adhiambo, A. Klimov, A.M. Fry); California Department of Public Health, Sacramento, California, USA (C.-Y. Pan); Wisconsin State Laboratory of Hygiene, Madison, Wisconsin, USA (E. Reisdorf); New York State Department of Health, Albany, New York, USA (K. St. George); Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA (R. Myers); Minnesota Department of Health, Saint Paul, Minnesota, USA (J.T. Wotton); Maine Department of Health and Human Services, Augusta, Maine, USA (S. Robinson); Washington State Department of Health, Shoreline, Washington, USA (B. Leader); Texas Department of State Health Services, Austin, Texas, USA (M. Thompson); Delaware Health and Social Services, New Castle, Delaware, USA (M. Shannon)

Main Article

Table 1

Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009 virus infection, United States, October 1, 2010–July 31, 2011*

Characteristic No. with characteristic/total no. (%), n = 35
Male sex 19/35 (54)
Exposed to oseltamivir before specimen collection† 9/34 (26)
Exposed to another person using oseltamivir 0/15 (0)
Received 2010–11 influenza vaccine 6/22 (27)
Any chronic medical conditions 22/33 (67)
Chronic pulmonary disease, including asthma 10/33 (30)
Chronic cardiac disease 6/33 (18)
Diabetes mellitus 8/33(24)
Immunocompromising condition‡ 8/33(24)
Pregnancy 1/33 (3)
Other§ 10/33 (30)
Lived in a single-family household 14/22 (64)
Lived in a residential facility 1/22 (4)
Others in the household/residence were ill before patient’s illness 2/15 (13)
Traveled within 7 d before illness 2/18 (11)
Hospitalized during influenza illness 14/33 (42)
ICU admission 8/14 (57)
Died 3/34 (9)

*The median age of patients was 33 y (range 1 mo–78 y). ICU, intensive care unit.
†Nine patients began oseltamivir treatment prior to specimen collection; none received oseltamivir chemoprophylaxis.
‡Includes HIV/AIDS, malignancy, autoimmune disorder, solid organ transplant, stem cell transplant, and history of taking immunosuppressive therapy in the past year.
§Includes morbid obesity, obstructive sleep apnea, chronic liver disease, and neurologic or developmental disorders.

Main Article

1Additional members of the US Antiviral Resistance Surveillance Working Group who contributed data are listed at the end of this article.